Sell this ASX 100 stock now: Goldman Sachs

Why is the broker feeling bearish about this stock? Let's find out.

| More on:
Close up of a sad young woman reading about declining share price on her phone.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Now could be the time to sell ASX Ltd (ASX: ASX) shares.

That's the view of analysts at Goldman Sachs, which are feeling bearish about the ASX 100 stock.

What is the broker saying about this ASX 100 stock?

Goldman has been looking at the stock exchange operator ahead of its results next month.

It believes there are a number of key issues and trends for investors to look out for. The first is divisional trends. It said:

1) Divisional trends: a) Listings benign: Listed entities declined over 2H24 but fee increases could offset this pressure. Compared to 1H24, IPO volumes were benign and secondary raisings slightly softer. Any recovery here will be lagged as revenues are amortised. b) Derivatives/ Futures strong: over 2H24 v 1H24 benefiting from interest rate volatility. c) Cash market trading up on 1H24: with an improvement through late 2H24 – similar trend for CS.

And while Goldman expects improvements in collateral balances and fee changes, it sees corporate bonds as a drag. The broker adds:

2) Collateral balances expected to improve over 2H24: Albeit ASX flagged stability in the investment spread at 10bps but expected this to increase over time. 3) Corporate bonds: issuance likely to be a slight drag on interest income as deployed. 4) Fee changes: Listing fees generally up ~5% on average we think across Jul-24/Jan-25. We also note fee increases in Austraclear across holding and transaction fees.

Also worth looking out for are movements in its equity investments and regulatory risks. It commented:

5) Equity investment portfolio: a) Sympli: Implications for Sympli from ARNECC pausing the interoperability program and standing down their project team. We expect small losses from Sympli to persist. b) Grow Inc: Update on profitability and participation in latest funding round. 6) Other key issues: a) Progress on ASIC's investigation into suspected contraventions of the ASIC Act 2001 and the Corporations Act 2001 in relation to the CHESS replacement program — see here — suggesting potential regulatory risks. b) Despite regulatory changes being implemented, we think the threat of competition is low, noting Capex requirements.

Sell rating retained

The note reveals that Goldman has held firm with its sell rating on the ASX 100 stock with an improved price target of $59.50.

Based on its current share price of $64.41, this implies potential downside of 7.6% for investors over the next 12 months.

The broker concludes:

We are Sell rated on ASX because: 1) Capex guidance remains elevated into FY25-FY27 from ongoing CHESS replacement project and technology revamp with risks on execution. 2) Risks arising from enhanced regulatory scrutiny on CHESS replacement and ASIC investigation. 3) Potential upside from a recovery in cyclical revenues is likely to be small with D&A drag to result in very muted earnings growth. 4) ASX's Clearing and Settlement ROE is well below Group ROE target.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

Broker looking at the share price.
Broker Notes

Broker ratings on 6 ASX shares about to join the ASX 200

These 6 companies will enter the ASX 200 in the December quarter rebalance. Should you buy them?

Read more »

A happy elderly woman smiles and cheers as she looks at good investment news on her laptop.
Broker Notes

Macquarie forecasts this $3.4 billon ASX healthcare share is set surge 33%

Macquarie tips material outperformance from this ASX healthcare share in 2026.

Read more »

Man looking at digital holograms of graphs, charts, and data.
Broker Notes

3 reasons this ASX 300 tech stock is forecast to leap 83% in 2026

A leading broker expects some outsized returns from this ASX 300 tech share. Let’s see why.

Read more »

gold share price represented by speeding golden bullet
Broker Notes

Why this surging ASX All Ords gold stock is tipped to rocket another 233%

A leading broker expects outsized gains from this ASX All Ords gold stock. But not without risk.

Read more »

A blockchain investor sits at his desk with a laptop computer open and a phone checking information from a booklet in a home office setting.
Broker Notes

3 buy-rated ASX 300 shares at 52-week lows

They've fallen far over the past 12 months but have buy ratings from the experts.

Read more »

Two happy excited friends in euphoria mood after winning in a bet with a smartphone in hand.
Broker Notes

Bell Potter names more of the best ASX 200 shares to buy in December

These are best buys according to the broker. Here's what it is saying about them.

Read more »

A young man pointing up looking amazed, indicating a surging share price movement for an ASX company
Broker Notes

These ASX 200 shares could rise 30% to 40% in 2026

Looking for big returns? Analysts think these shares could beat the market.

Read more »

Ecstatic woman looking at her phone outside with her fist pumped.
Broker Notes

Analysts name 3 ASX shares to buy this week

Analysts have good things to say about these shares.

Read more »